Switching or Transitioning Between Wegovy vs Zepbound: Questions to Ask a Prescriber
Switching between Wegovy and Zepbound is common and clinically routine, but it is not a swap. There is no dose equivalence between semaglutide and tirzepatide, so a transition normally means starting the new drug at its own introductory dose and escalating again. That reset is the single most important thing to understand before deciding, because it costs months and it is the reason a switch made for the wrong reason often backfires.
Reviewed by Dr. Anita Petruzzelli, MD, OB-GYN
Why there is no equivalent dose
The two are different molecules with different receptor targets. Semaglutide acts on the GLP-1 receptor. Tirzepatide acts on both GLP-1 and GIP receptors. Their dosing scales were established independently in separate trial programs, and no milligram figure on one translates to the other.
Practically, this means a person at the top dose of one drug does not move to a comparable dose of the other. They start near the bottom of the new drug’s range and work upward on its own schedule. Expecting otherwise is the most frequent source of disappointment after a switch.
Reasons that usually justify switching
Some reasons hold up well. Coverage changing so that one drug is affordable and the other is not is a sound reason, since a drug you cannot obtain has no effect. Persistent supply problems with one product fall into the same category.
A genuine efficacy plateau is also reasonable, provided it is a real plateau. That means having reached and sustained a meaningful dose for long enough to judge, rather than concluding at a starting dose that the drug does not work. Developing a condition with an approved indication held by only one of the products can justify a switch as well, because it changes the coverage pathway.
Because affordability is one of the few reasons a switch clearly makes sense, it helps to know what each drug would cost through the route you would actually use. The field is not uniform: Ro and Hims and Hers wrap the medication into a monthly membership, LillyDirect and NovoCare hand patients off to the brand makers’ self-pay programs, and providers such as HealthRX publish a Wegovy vs Zepbound price comparison openly, which lets you check whether a switch made for cost genuinely lands somewhere cheaper. Doing that arithmetic before transitioning avoids trading one unaffordable option for another.
Reasons that usually do not
Switching to escape gastrointestinal side effects disappoints often. Both drugs act on the GLP-1 receptor, both slow gastric emptying, and both produce mainly the same category of effect. Worse, escalation restarts, and escalation is when those effects peak, so the immediate result of the switch can be a return to the hardest phase.
Switching early because results feel slow is the other common misstep. Both drugs require months of escalation before reaching studied doses, so an early response reflects tolerance rather than efficacy. Abandoning at that point and restarting elsewhere resets the clock without answering the question.
| Reason for switching | Generally sound? |
|---|---|
| Coverage or affordability changed | Yes |
| Persistent supply problems | Yes |
| Plateau at a sustained meaningful dose | Yes |
| New condition with an approved indication | Yes |
| Escaping gastrointestinal effects | Often not, shared mechanism |
| Slow results at a starting dose | No, too early to judge |
Questions to settle before transitioning
Ask what starting dose the new drug will begin at and what the escalation schedule looks like, so the timeline is explicit rather than assumed. Ask how long the gap between the last dose of one and the first dose of the other should be, since both are weekly and the timing is a clinical decision rather than a matter of convenience.
Ask what happens to side effects during the transition, and at what point the prescriber would pause escalation. Ask what would count as evidence that the switch worked, and at what point that judgment should be made, so the decision is not revisited every fortnight.
Ask whether any other medication needs adjusting at the same time, particularly diabetes medication. Ask what the sustained monthly cost will be on the new drug rather than the first month, and what happens if coverage changes again. Providers publishing flat monthly pricing, such as FormBlends, make that last question easier to answer in advance, which matters when the whole reason for switching was cost in the first place.
Keep a record of what came before
The most useful thing to bring to a transition is an accurate history of the drug being left behind. That means the highest dose reached, how long it was sustained, what the weight trajectory looked like at that dose, and which side effects appeared at which point.
This matters because it converts a vague impression into evidence a prescriber can use. Someone reporting that a drug stopped working has said little. Someone reporting that they held the top dose for five months with a flat trajectory and manageable side effects has described a genuine plateau, which points somewhere specific.
It also protects against repeating a pattern. If a record shows that previous escalations were abandoned early each time, the problem may be the pace rather than the molecule, and a fourth drug will not fix it.
What to expect in the first weeks
Expect the gastrointestinal effects associated with early escalation to return, since you are re-entering that phase. Expect appetite suppression to feel weaker initially than it did at your previous dose, because the new dose is lower in its own range.
Expect the weight trajectory to flatten or move slightly in the wrong direction during the transition. That is a normal consequence of dropping to a lower effective dose, not evidence the new drug has failed. Judging the switch requires reaching a meaningful dose on the new drug, which takes months rather than weeks.
A note on compounded products
Transitions involving compounded semaglutide or tirzepatide need particular care. These are not FDA-approved products, and concentration and formulation can differ between pharmacies, so assumptions carried over from a brand product may not hold. The prescribing clinician needs to know exactly what was being taken, at what concentration, and from where.
Frequently asked questions
Is there a conversion between semaglutide and tirzepatide doses?
No. They are different molecules with separately established dosing scales, and no milligram figure on one translates to the other. A switch normally restarts at the new drug’s introductory dose.
How long does a switch take to evaluate?
Months rather than weeks, because the new drug must be escalated to a meaningful dose before its effect can be judged. Assessing at a starting dose repeats the mistake that often prompted the switch.
Will side effects be worse after switching?
Often temporarily, because escalation is when effects peak and escalation restarts. This is the main reason switching purely to avoid side effects frequently disappoints.
Can you switch back?
Yes, but each move restarts escalation again. Repeated switching can leave someone spending most of their treatment time at sub-therapeutic doses, which produces worse results than staying put.
Should there be a gap between the two drugs?
That is a clinical decision that depends on the last dose taken and the timing of the weekly schedule. It should be specified by the prescriber rather than estimated.
